Catawba Research

Catawba Research

Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

Catawba Research is a well-established, private CRO with nearly four decades of experience managing complex clinical trials. It leverages a nimble, client-tailored approach ('The Catawba Way') and deep scientific leadership to guide sponsors from early clinical programs to market authorization. Recent strategic moves, including a partnership with PharmaLegacy Laboratories and the establishment of Catawba Research India, demonstrate an expansion of its end-to-end service capabilities and global footprint, particularly in the Asia-Pacific region. The company positions itself as a trusted partner for sponsors seeking efficient, high-quality trial execution.

Infectious DiseaseDiagnostics

Technology Platform

Integrated clinical trial service delivery platform ('The Catawba Way') emphasizing agile project management, active scientific leadership, regulatory-compliant quality systems, and global data management capabilities.

Opportunities

Expansion into the high-growth APAC clinical trial market, particularly China, through the PharmaLegacy partnership.
Growing demand for integrated preclinical-to-clinical services and specialized expertise in regulatory pathways like 505(b)(2) from small to mid-sized biopharma sponsors.

Risk Factors

Revenue dependency on the cyclical biopharma R&D funding environment and intense competition from larger global CROs.
Operational risks related to trial execution, data quality, and regulatory compliance, which could impact reputation and liability.

Competitive Landscape

Operates in the highly competitive global CRO market, competing against large full-service players (e.g., IQVIA, ICON) and numerous niche CROs. Differentiates through its agile, client-tailored approach ('The Catawba Way'), deep experience in specific sectors like infectious disease, and expertise in complex regulatory pathways such as 505(b)(2).